Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Germeau, C. Articles by Coulie, P. G. Search for Related Content PubMed PubMed Citation Articles by Germeau, C. Articles by Coulie, P. G. Related Collections Related Article Social Bookmarking                      What's this?

¹ Cellular Genetics Unit, Université de Louvain, B-1200 Brussels, Belgium
² Ludwig Institute for Cancer Research, Brussels Branch, B-1200 Brussels, Belgium
³ Medical Oncology, Erasme Hospital, B-1070 Brussels, Belgium

CORRESPONDENCE Pierre G. Coulie: coulie{at}gece.ucl.ac.be

After vaccination of melanoma patients with MAGE antigens, we observed that even in the few patients showing tumor regression, the frequency of anti-vaccine T cells in the blood was often either undetectable or <10^–5 of CD8 T cells. This frequency being arguably too low for these cells to be sole effectors of rejection, we reexamined the contribution of T cells recognizing other tumor antigens. The presence of such antitumor T cells in melanoma patients has been widely reported. To begin assessing their contribution to vaccine-induced rejection, we evaluated their blood frequency in five vaccinated patients. The antitumor cytotoxic T lymphocyte (CTL) precursors ranged from 10^–4 to 3 x 10^–3, which is 10–10,000 times higher than the anti-vaccine CTL in the same patient. High frequencies were also observed before vaccination. In a patient showing nearly complete regression after vaccination with a MAGE-3 antigen, we observed a remarkably focused antitumoral response. A majority of CTL precursors (CTLp's) recognized antigens encoded by MAGE-C2, another cancer-germline gene. Others recognized gp100 antigens. CTLp's recognizing MAGE-C2 and gp100 antigens were already present before vaccination, but new clonotypes appeared afterwards. These results suggest that a spontaneous antitumor T cell response, which has become ineffective, can be reawakened by vaccination and contribute to tumor rejection. This notion is reinforced by the frequencies of anti-vaccine and antitumor CTLs observed inside metastases, as presented by Lurquin et al. (Lurquin, C., B. Lethé, V. Corbière, I. Théate, N. van Baren, P.G. Coulie, and T. Boon. 2004. J. Exp. Med. 201:249–257).

C. Germeau and W. Ma contributed equally to this work.

F. Schiavetti's present address is Glaxo-SmithKline Bio, 1330 Rixensart, Belgium.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Jump-starting tumor-specific T cells

Heather L. Van Epps
J. Exp. Med. 2005 201: 163. [Full Text] [PDF]

This article has been cited by other articles:

• Connerotte, T., Van Pel, A., Godelaine, D., Tartour, E., Schuler-Thurner, B., Lucas, S., Thielemans, K., Schuler, G., Coulie, P. G. (2008). Functions of Anti-MAGE T-Cells Induced in Melanoma Patients under Different Vaccination Modalities. Cancer Res. 68: 3931-3940 [Abstract] [Full Text]  
• Goldberger, O., Volovitz, I., Machlenkin, A., Vadai, E., Tzehoval, E., Eisenbach, L. (2008). Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape. Cancer Res. 68: 3450-3457 [Abstract] [Full Text]  
• Carrasco, J., Van Pel, A., Neyns, B., Lethe, B., Brasseur, F., Renkvist, N., van der Bruggen, P., van Baren, N., Paulus, R., Thielemans, K., Boon, T., Godelaine, D. (2008). Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells. J. Immunol. 180: 3585-3593 [Abstract] [Full Text]  
• Lengagne, R., Graff-Dubois, S., Garcette, M., Renia, L., Kato, M., Guillet, J.-G., Engelhard, V. H., Avril, M.-F., Abastado, J.-P., Prevost-Blondel, A. (2008). Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases. J. Immunol. 180: 130-137 [Abstract] [Full Text]  
• Inokuma, M., dela Rosa, C., Schmitt, C., Haaland, P., Siebert, J., Petry, D., Tang, M., Suni, M. A., Ghanekar, S. A., Gladding, D., Dunne, J. F., Maino, V. C., Disis, M. L., Maecker, H. T. (2007). Functional T Cell Responses to Tumor Antigens in Breast Cancer Patients Have a Distinct Phenotype and Cytokine Signature. J. Immunol. 179: 2627-2633 [Abstract] [Full Text]  
• Elliott, B., Scolyer, R. A., Suciu, S., Lebecque, S., Rimoldi, D., Gugerli, O., Musat, E., Sharma, R. N., Lienard, D., Keilholz, U., Testori, A., Eggermont, A., MacKie, R., Robert, C., Cook, M., Thompson, J. F., Angevin, E., Spatz, A., on behalf of the European Organization for Researc, (2007). Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma. Clin. Cancer Res. 13: 3825-3830 [Abstract] [Full Text]  
• Ferrone, C. R., Perales, M.-A., Goldberg, S. M., Somberg, C. J., Hirschhorn-Cymerman, D., Gregor, P. D., Turk, M. J., Ramirez-Montagut, T., Gold, J. S., Houghton, A. N., Wolchok, J. D. (2006). Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin fc domains.. Clin. Cancer Res. 12: 5511-5519 [Abstract] [Full Text]  
• Shimizu, K., Hidaka, M., Kadowaki, N., Makita, N., Konishi, N., Fujimoto, K., Uchiyama, T., Kawano, F., Taniguchi, M., Fujii, S.-i. (2006). Evaluation of the Function of Human Invariant NKT Cells from Cancer Patients Using {alpha}-Galactosylceramide-Loaded Murine Dendritic Cells.. J. Immunol. 177: 3484-3492 [Abstract] [Full Text]  
• Inoue, S., Leitner, W. W., Golding, B., Scott, D. (2006). Inhibitory effects of B cells on antitumor immunity.. Cancer Res. 66: 7741-7747 [Abstract] [Full Text]  
• Speiser, D. E., Baumgaertner, P., Barbey, C., Rubio-Godoy, V., Moulin, A., Corthesy, P., Devevre, E., Dietrich, P.-Y., Rimoldi, D., Lienard, D., Cerottini, J.-C., Romero, P., Rufer, N. (2006). A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by Vaccination. J. Immunol. 177: 1338-1348 [Abstract] [Full Text]  
• Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., Neefjes, J. J. (2006). Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203: 1259-1271 [Abstract] [Full Text]  
• Di Pucchio, T., Pilla, L., Capone, I., Ferrantini, M., Montefiore, E., Urbani, F., Patuzzo, R., Pennacchioli, E., Santinami, M., Cova, A., Sovena, G., Arienti, F., Lombardo, C., Lombardi, A., Caporaso, P., D'Atri, S., Marchetti, P., Bonmassar, E., Parmiani, G., Belardelli, F., Rivoltini, L. (2006). Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-{alpha} Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors.. Cancer Res. 66: 4943-4951 [Abstract] [Full Text]  
• Vuylsteke, R. J.C.L.M., Molenkamp, B. G., van Leeuwen, P. A.M., Meijer, S., Wijnands, P. G.J.T.B., Haanen, J. B.A.G., Scheper, R. J., de Gruijl, T. D. (2006). Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF-Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content.. Clin. Cancer Res. 12: 2826-2833 [Abstract] [Full Text]  
• Uemura, H., Fujimoto, K., Tanaka, M., Yoshikawa, M., Hirao, Y., Uejima, S., Yoshikawa, K., Itoh, K. (2006). A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma.. Clin. Cancer Res. 12: 1768-1775 [Abstract] [Full Text]  
• van Baren, N., Bonnet, M.-C., Dreno, B., Khammari, A., Dorval, T., Piperno-Neumann, S., Lienard, D., Speiser, D., Marchand, M., Brichard, V. G., Escudier, B., Negrier, S., Dietrich, P.-Y., Maraninchi, D., Osanto, S., Meyer, R. G., Ritter, G., Moingeon, P., Tartaglia, J., van der Bruggen, P., Coulie, P. G., Boon, T. (2005). Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells. JCO 23: 9008-9021 [Abstract] [Full Text]  
• Gure, A. O., Chua, R., Williamson, B., Gonen, M., Ferrera, C. A., Gnjatic, S., Ritter, G., Simpson, A. J.G., Chen, Y.-T., Old, L. J., Altorki, N. K. (2005). Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non-Small Cell Lung Cancer. Clin. Cancer Res. 11: 8055-8062 [Abstract] [Full Text]  
• Rosenberg, S. A., Sherry, R. M., Morton, K. E., Scharfman, W. J., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U., Restifo, N. P., Hughes, M. S., Schwartzentruber, D., Berman, D. M., Schwarz, S. L., Ngo, L. T., Mavroukakis, S. A., White, D. E., Steinberg, S. M. (2005). Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma. J. Immunol. 175: 6169-6176 [Abstract] [Full Text]  
• Vignard, V., Lemercier, B., Lim, A., Pandolfino, M.-C., Guilloux, Y., Khammari, A., Rabu, C., Echasserieau, K., Lang, F., Gougeon, M.-L., Dreno, B., Jotereau, F., Labarriere, N. (2005). Adoptive Transfer of Tumor-Reactive Melan-A-Specific CTL Clones in Melanoma Patients Is Followed by Increased Frequencies of Additional Melan-A-Specific T Cells. J. Immunol. 175: 4797-4805 [Abstract] [Full Text]  
• van Houdt, I. S., Oudejans, J. J., van den Eertwegh, A. J.M., Baars, A., Vos, W., Bladergroen, B. A., Rimoldi, D., Muris, J. J.F., Hooijberg, E., Gundy, C. M., Meijer, C. J.L.M., Kummer, J. A. (2005). Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients with Stage III and IV Melanoma. Clin. Cancer Res. 11: 6400-6407 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS